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Abstract 
Although venous thromboembolism (VTE) is quite common in patients suffering from different stages of cancer, 
it is still an underestimated problem. Oncological treatment, surgeries, and advanced-stage cancer are only 
some risk factors for VTE, which is one of the most common causes of death in cancer patients. Differences in 
the risk of deep-venous thrombosis and its complications, including risk of bleeding, between particular onco-
logical patient groups suggests that there is a need for individual risk assessment and prophylaxis dedicated to 
specific clinical situations and patients. They also give grounds for constant update of guidelines on prophylaxis 
in cancer patients. This document contains venous thromboembolism prophylaxis guidelines in oncology patients 
with focus on surgical cancer.
Key words: venous thromboembolism, cancer, cancer surgery, VTE prophylaxis, anti-cancer 
treatment
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Introduction
Venous thromboembolism affects various popula-
tions of patients, including those suffering from cancer 
who are at a higher risk of deep venous thrombosis 
and pulmonary embolism. Considering the need for 
actions aiming at decreasing the number of throm-
boembolic complication cases in cancer patients, this 
document presents guidelines based on up-to-date 
medical knowledge regarding recommendations and 
rules of antithrombotic treatment in cancer patients, 
especially those who are undergoing surgery on that 
account. 
Proposed guidelines on venous thromboembolism 
apply to adult patients treated due to oncological 
reasons; please note that these guidelines do not re-
fer to children. The guidelines are meant for medical 
professionals of different fields and medical workers 
participating in diagnostics and treatment of cancer 
patients. Up-to-date scientific data was analyzed along 
with guidelines on venous thromboembolism that have 
been published until recently in Poland and abroad with 
the focus on guidelines referring to cancer patients 
for their elaboration. Prophylaxis guidelines were 
formulated based on medicine based evidence (EBM) 
in order to form an universal document dedicated to 
cancer patients, who remain under supervision of a 
specialist, as well as those who are treated by general 
practitioners. The authors also attempted to adjust 
these guidelines as much as possible to the present 
healthcare system in Poland.
Guidelines represent the standpoint of the authors 
on most-justified diagnostic and therapeutic proce-
dures, however, they should be interpreted in the 
context of each individual clinical situation. These guide-
lines should not be treated as mandatory treatment 
or a medical standard. Just like other guidelines, they 
are above all indications aiming to enable and facilitate 
rational clinical decisions regarding prophylaxis and 
treatment of venous thromboembolism in cancer pa-
tients. This document is based on scientific reports that 
are available at this moment. The authors of this work 
believe that it will require further updates along with 
new reports and study results that consider this issue.
Katowice, August 1, 2016
Methods, guidelines classification
During the elaboration of this document all the avail-
able references were analyzed and guidelines were for-
mulated based on definitions according to the GRADE 
Working Group (The Grading of Recommendations Assess­
ment Development and Evaluation Scale). Formulated 
guidelines were classified as strong recommendations 
— [1] or weak recommendations — [2] and supported 
with an additional description referring to the quality 
of evidence that they have been based on. In the case 
of recommendations classified as strong, based on the 
analysis of results of correctly planned and performed 
studies, the authors are convinced that administration 
of a particular procedure will bring significant benefits 
in comparison to restraining from it (recommendation 
level 1 — “recommended”). In case of a weak recom-
mendation (recommendation level 2 — “suggested”) 
the authors believe that administration of the suggested 
procedures may be more beneficial than restraining 
from performing it. However, at this point, there are no 
high — quality studies that would determine favorable 
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and unfavorable effects of a particular procedure — 
this recommendation level should be considered as 
a suggestion for the final clinical decision. 
According to the suggestions specified in GRADE, 
guidelines marked with letter (A) are based on reports 
sufficient for formulating them and further studies prob-
ably will not elicit any changes. The letter (B) indicates 
that further studies could possibly influence the change 
of statement due to the quality of data available at this 
time. The letter (C) suggests that due to very low quality 
of data available, further studies may elicit significant 
changes to the guidelines.
The levels of recommendation importance:
1A — strong recommendation, high-quality evidence 
according to EBM*; 
1B — strong recommendation, moderate-quality evi-
dence according to EBM; 
1C — strong recommendation, low- or very low-quality 
scientific evidence;
2A — weak recommendation, high-quality evidence 
according to EBM (further studies probably will not 
have any significant influence on changes in suggested 
treatment method);
2B — weak recommendation, moderate-quality evid-
ence according to EBM (further studies may have 
significant influence on changes in suggested treatment 
method);
2C — weak recommendation, low- or very low-quality 
scientific evidence (further studies probably will have 
significant influence on changes in suggested treatment 
method).
The authors reviewed papers on prophylaxis and 
the treatment of cancer patients using the MEDLINE 
database from January 1, 1995 to January 31, 2016. The 
analysis covered available randomized trials, prospec-
tive and retrospective studies, as well as meta-analysis, 
systematic reviews, and previously published Polish and 
foreign guidelines on prophylaxis and the treatment 
of venous thromboembolism (VTE), including VTE 
prophylaxis in cancer patients [4–31].
Chapter 1. Venous thromboembolism 
prophylaxis — general recommendations
According to up-to-date guidelines for prophy-
laxis and the treatment of venous thromboembolism 
(including: “Polish guidelines for the prevention and 
the treatment of venous thromboembolism — 2012”, 
“Antithrombotic Therapy and Prevention of Throm-
bosis, 9th ed.: American College of Chest Physicians 
Evidence-Based Clinical Practice Guidelines — 2012”) 
the authors of guidelines for cancer patients stand by 
the general recommendations on prevention of throm-
bosis, formulated in the above-mentioned documents 
[13, 14]:
Guideline 1.1
It is recommended to elaborate and implement 
guidelines for VTE prophylaxis in every hospital, de-
partment and/or institute, where the cancer patients 
at risk of venous thromboembolism are treated and 
consulted [1A].
Guideline 1.2
It is recommended to elaborate guidelines for VTE 
prophylaxis on paper or in electronic form, as a standard 
procedure for particular health care facility [1C].
Guideline 1.3
It is recommended to use anticoagulants for VTE 
prophylaxis and treatment according to manufacturer 
guidelines and drug registration documents [1C].
Guideline 1.4
In patients with a high bleeding risk, benefits and 
risk of antithrombotic prophylaxis should be evaluated 
individually. In clinically justified situations, mechanical 
prophylaxis methods should be applied, until bleeding 
risk will decrease enabling the administration of phar-
macological prophylaxis [1A].
Comment
Individual risk assessment of venous thromboem-
bolism is justified considering the variety of clinical 
situations and differentiated characteristic of patients 
treated in particular health care facilities, and de-
partments in view of treatment form, and risk factor 
characteristic of the particular patient’s group. At the 
same time, significant differences between populations 
of patients indicate a need for the elaboration of an 
antithrombotic prophylaxis protocol dedicated to 
the particular patient group in each healthcare facility 
considering the characteristics of the treated popu-
lation, as well as administered therapy. This protocol 
should be prepared on paper and in electronic form 
considering recommendations on risk assessment 
and prophylaxis of venous thromboembolism as well 
as up-to-date authorizations of available and admin-
istered drugs aimed for this indication. Guidelines on 
antithrombotic prophylaxis in the particular healthcare 
facility should be elaborated considering up-to-date 
guidelines, as well as an individual risk assessment for 
venous thromboembolism, treatment-related bleed-
ing and potential complications caused by pharmaco-
logical prophylaxis in the particular group of patients. 
*EBM — Evidence Based Medicine
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Chapter 2. The prevention of venous 
thromboembolism in cancer patients 
treated surgically
Venous thromboembolism often occurs in the nat-
ural course of cancer disease [32]. At the same time, 
however, attempts of treatment, especially surgical 
treatment, increase the risk of this complication [4, 9, 
10, 14, 15, 32, 33]. Surgery affects the risk of throm-
bosis through multiple factors; tissue trauma due to 
surgical procedures, periprocedural immobilization, 
blood and plasma substitution, positive pressure ven-
tilation, potential inflammation foci or intravenous 
catheters [14, 34–39].
Patients qualified for surgery who are diagnosed 
with malignancy are three times as much in risk of 
deep vein thrombosis and twice in risk of pulmonary 
embolism as patients without a diagnosed cancer [34, 
35, 40–44]. Because of oncological indications, in most 
cases of cancer patients qualified for surgical treatment, 
we should assume the population of these patients as 
high risk and very high risk of VTE [4, 14, 15]. The 
increased risk is also reflected in the proposed models 
of thromboembolic complication risk assessment, such 
as in the perioperative risk of VTE scale proposed by 
Caprini, in which the presence of cancer corresponds 
to 2 points (Table 1) [15, 45–47]. 
According to current knowledge, while evaluating 
the risk of VTE, it is extremely important to take into 
consideration the presence of other risk factors, espe-
cially those related to the presence of comorbidities 
and a clinical condition causing an increased risk of 
VTE (obesity, prolonged immobilization, varicose veins, 
hormonal therapy, previous cerebrovascular event 
resulting in paralysis, prior episode of VTE and other) 
[14, 15, 48]. It must be emphasized that diseases re-
cently defined as in the spectrum of nonsurgical medical 
fields, are among currently recognized risk factors of 
VTE. Among them are the worsening of chronic heart 
failure or inflammatory bowel diseases [14, 15, 21]. 
One should also keep in mind other potential risk factors, 
such as postsurgical infections — the presence of an in-
tra-abdominal abscess or other infections of the surgical 
site following colorectal surgery or other acute infection 
may increase the risk of VTE [15, 49–51]. Merkow et 
al. analyzed the incidence of postsurgical VTE in cancer 
patients (a population of 44 656 patients with 9 types 
of cancer) and documented that as 33.4% of cases 
with VTE occurred not immediately before the proce-
dure, but right after discharge from the hospital (with 
varying proportions of patients with deep vein throm-
bosis depending on the type of cancer treated) [52]. 
Among other factors that significantly affect the in-
cidence of VTE in this group, the following were re-
cognized: age ≥ 65 years, presence of metastases, high 
BMI, level of thrombocytes over 400 000, albumin level 
< 3.0 g/dL and duration of the procedure being over 
2 hours. VTE cases were more frequently observed in 
patients surgically treated for gastrointestinal tract, lung 
and prostate cancer, as well as in those patients with 
surgery performed on the ovaries/uterus. The fact that 
patients with an episode of VTE have a six times higher 
mortality rate is also worth noticing. Other authors also 
report a significant increased risk of VTE during remote 
periods of time post-surgery (after discharge). Alusbaie 
et al. analyzed retrospectively the results of 6612 “ma-
jor” cancer surgery cases involving the abdominal and 
pelvic areas and identified 4.05% of symptomatic VTE 
up to 90 days after treatment, of which 47.5% to be 
diagnosed after discharge [53]. Prior cancer therapy 
including chemotherapy and presurgical radiotherapy 
influence the general risk of thrombosis [54]. 
However, not only cancer surgery in the abdominal, 
pelvic and thorax areas is linked to risk of thrombosis. 
Reports of VTE occurrences are followed by other 
cancer surgery procedures of the head and neck, 
which include oral and maxillofacial surgery procedures 
or also commonly performed breast cancer surgery 
[55–60]. According to Tran et al. the risk of overt VTE in 
a population of 49 028 patients undergoing mastectomy 
amounted to 0.23% [58]. Similar data was presented 
by De Martino et al. suggesting the presence of 0.19% 
of symptomatic deep vein thrombosis, pulmonary 
embolism 0.12% and 0.28% of VTE within 30 days 
after breast cancer surgery [59]. Lovely et al. report 
about 0.5% of cases of VTE in patients undergoing 
surgery for breast cancer reasons [60]. The authors 
of the above-mentioned studies also point to potential 
risk factors in this population other than just cancer 
presence [58–60].
The effectiveness of low doses of heparin (low doses 
of unfractionated heparin — LDUH) in the prevention 
of VTE in high risk surgical patients has been docu-
mented for many years, however, in everyday clinical 
practice, partly of practical reasons, this method of 
prophylaxis plays a marginal role in comparison with the 
very common use of the low molecular weight heparin 
(LMWH) in this indication [61–70]. In controlled ran - 
domized trials comparing LMWH with LDUH in patients 
undergoing cancer surgical treatment, both methods of 
prevention have a high and comparable efficacy [68, 71]. 
Comparative studies on the efficacy of unfractionated 
and low molecular weight heparin in VTE prevention 
in the perioperative period in the cancer patients were 
evaluated in a meta-analysis involving 16 prospective 
clinical trials performed on a total population of 12 890 
patients [72]. The use of LMWH compared to LDUH 
was associated with a similar mortality rate (RR 0.89; 
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Table 1. Modified Caprini scale to assess the risk of thromboembolic complications in surgical patients [according to 15]
1 point 2 points 3 points 5 points
Age 41–60 years
Small surgery
BMI > 25 kg/m2
Edema of the lower limbs
Varicose veins of the lower 
limbs
Pregnancy or postpartum 
period
Or a history of unexplained 
recurrent miscarriages
Oral contraceptives or hor-
mone replacement therapy
Sepsis (< 1 month)
An acute lung disease,  
including pneumonia  
(< 1 month)
Lung disorders 
Acute myocardial infarction
Exacerbation or diagnosis of 
heart failure (< 1 month)
History of inflammatory  
bowel disease
The patient is undergoing 
conservative treatment,  
remains in bed
Age 61–74 years
Arthroscopic surgery
Major surgery (> 45 min)
Laparoscopic surgery  
(> 45 min)
Cancer
Remaining in bed (> 72 h)
Plaster cast with immobili-
zation
Central venous catheter
Age ≥ 75 years
History of VTE
VTE in family history
Factor V Leiden
G20210A prothrombin gene 
mutation
Lupus anticoagulant
Anticardiolipin antibodies
Anti-b2-GPI
Increased levels of serum 
homocysteine
Heparin-induced thrombo-
cytopenia (HIT)
Other congenital or acquired 
thrombophilia
Stroke (< 1 month)
Elective arthroplasty
Fracture of the pelvis, femur 
or shin bone
Acute spinal cord injury  
(< 1 month) 
Scoring: 0 points — very small risk; 1–2 points — low risk; 3–4 points — average risk; ≥ 5 points — high risk
95% CI 0.74–1.08), similar incidence of pulmonary 
embolism (RR: 0.73; 95% CI 0,34–1. 54), similar rate of 
symptomatic deep vein thrombosis (RR: 0.50; 95% CI 
0.20–1.28) and a similar incidence of “major” bleeding 
complications (RR: 0.85; 95% CI 0.52–1.37) [72].
When using LDUH and LMWH in DVT prophylaxis 
in surgical oncology, according to indications as well 
as previously performed research, pharmacological 
prophylaxis should begin prior to the surgical procedure 
[4, 9, 68, 70]. So far, there are no reports of clinical 
trials or the registration of any new oral anticoagulants 
in thrombosis prophylaxis both in the field of surgery 
and surgical oncology.
Apart from the time of the start of the prophylaxis, 
an important issue concerning perioperative VTE 
prophylaxis in cancer patients is the heparin dose and 
duration of prophylaxis. The authors of this document 
agree that it is crucial to adhere to the registration 
documents of certain drugs and use them as indicated 
in those documents. Some of the products containing 
LMWH have a choice of different prophylactic dosage 
options for the moderate and high risk surgical patients, 
however, there are suggestions supported by research 
that higher doses should be used in high and very high 
risk cancer patients. In a study of 1.375 patients, of 
whom 70% were patients with cancer, two prophylactic 
doses of dalteparin (2500 U and 5000 U) were used. 
The dose 5000 U was more effective in preventing 
postoperative VTE than the 2500 U dose (postoperative 
VTE of 8.5% vs. 14.9%; p < 0.001) [73]. 
Currently, there are still very few randomized pro-
spective studies comparing the efficacy of the different 
LMWHs in this indication. In the SAVE-ABDO study, in 
which more than 80% of the 4414 patients were those 
who undergo major surgery in the abdominal area due 
to cancer, the patients were randomized to the groups 
receiving enoxaparin or semuloparin (the beginning 
of prophylaxis in both groups before the procedure). 
Endpoints defined in this study as an episode of VTE 
or death occurred in 5.5% of patients receiving enoxa-
parin and in 6.3% of those receiving semuloparin (OR 
1.16; 95% CI, 0.84–1.59) with a smaller percentage of 
bleeding complications in the group receiving semulo- 
parin [74]. In a study comparing the efficacy of nadroparin 
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or enoxaparin at prophylactic doses (nadroparin: 2850 U 
anti-Xa, enoxaparin 4000 U anti-Xa) in surgical patients 
with colo-rectal cancer, symptomatic or asymptomatic 
DVT or pulmonary embolism occurring up to 12 days of 
observation, was diagnosed respectively in 15.9% and 
12.6% of those patients (RR 1.27; 95% CI 0.93 to 1.74, 
p = NS) with fewer major bleeding complications in the 
group treated with nadroparin (7.3% vs. 11.5%; p < 0.05) 
— in this context, from a methodological standpoint 
one must notice that administering enoxaparin in 
a dose of 40 mg (respectively 2, instead of the currently 
recommended 12 hours before surgery) differed from 
what is indicated now by the manufacturer [75]. The 
comparison of dalteparin in a dose of 5000 U anti-Xa 
with fondaparinux 2.5 mg administered once a day for 
5 to 9 days revealed comparable indicators of benefits/ 
/risk for both drugs in perioperative prophylaxis in surgical 
patients [76]. In the case of fondaparinux, however, there 
is still a lack of prospective, randomized studies dedicated 
specifically to the population of cancer patients — in the 
mentioned above PEGASUS study, they represented 
only a small portion of the population studied [76, 77]. 
In most of the above mentioned research in patients 
undergoing major surgery in the abdominal and pelvic 
area, including surgical oncology, thrombosis prophylax-
is was administered up to 7–10 days after surgery, which 
according to current knowledge may be insufficient [4, 
14, 32, 33]. Conclusions from randomized clinical trials 
that relate to extended (up to 4 weeks) primary VTE 
postsurgical prophylaxis (ENOXACAN II — extended 
prophylaxis after major surgery in the abdominal and 
pelvis area; FAME — extended prophylaxis in exten-
sive surgery of the abdominal and pelvis area) indicate 
potential benefits of such management of surgical 
patients at high risk of thromboembolic complications 
[78, 79]. In both studies, 4 weeks of thromboembolic 
prophylaxis with low molecular weight heparin proved 
to be an effective means to reduce the incidence of VTE 
compared to the standard duration of prophylaxis (at 
the same time not increasing the percentage rate of 
bleeding) [78, 79]. At the moment, it should be consid-
ered rational to extend VTE prophylaxis with LMWH 
up to 4 weeks in patients undergoing extensive cancer 
surgery in the abdominal and/or pelvic areas and at 
a low risk of bleeding complications [78–82].
Rapid and aggressive mobilization of the patients 
after surgery is currently the standard of perioperative 
care. Often other mechanical methods of thrombo-
prophylaxis are also used. A number of already complet-
ed studies related to surgically treated patients highlight 
the beneficial effects of mechanical prophylaxis methods 
on the reduction of VTE incidence in this group of 
patients [14]. Most of them, however, relate only to 
mixed groups of patients, in terms of risk as well as in 
terms of indications for surgery. Reports dedicated to 
homogenous groups of cancer patients are very limited 
[77, 83–87].
According to available literature and most previously 
published guidelines, mechanical methods should not 
be used as the only thromboprophylaxis method in pa-
tients with a high risk of VTE under condition, however, 
that the patient is at low risk of bleeding complications 
which is a potential contraindication for pharmaco-
logical prophylaxis [4, 9, 14, 15]. On the other hand, 
concomitant prophylaxis with mechanical methods, in 
particular intermittent pneumatic compression (IPC), 
may have a beneficial additive effect on the reduction 
of thrombotic events in patients with a high and very 
high risk of VTE qualified for surgery [4, 9, 14, 15]. In 
a meta-analysis, the results of 25 prospective randomized 
clinical trials concerning the combined DVT prophylaxis 
based on anticoagulation and mechanical methods were 
compared with VTE prevention regimens using only 
one method of prophylaxis [88]. Based on this report, 
pharmacological prophylaxis with mechanical methods 
together resulted in 49% DVT risk reduction. On the 
other hand, an increased bleeding risk should also be 
considered when pharmacological prevention is used. 
The pharmacological VTE prophylaxis added to me-
chanical methods led to the 44% DVT risk decrease, 
however, a significant increase in the bleeding rate was 
observed (RR 1.74; 1.29–2.34) [88].
Laparoscopic oncological surgery
Data on effectiveness of VTE prophylaxis in lap-
aroscopic oncological surgery is limited [89–91]. Xie 
et al. in their meta-analysis of 9 randomized clinical 
trials conducted on 2606 cases of colorectal cancer, 
who underwent surgery, did not find any difference in 
DVT incidence between patients treated with open or 
laparoscopic surgery [91]. 
The guidelines of the Society of American Gas-
trointestinal and Endoscopic Surgeons dedicated to 
patients undergoing laparoscopic surgery and up-to-
date guidelines of other scientific societies emphasize 
that there are no prospective clinical trials of sufficient 
quality focusing on antithrombotic prophylaxis in 
cancer patients treated with laparoscopic surgery 
[9, 14, 92]. Factors related to laparoscopic surgery 
that increase the risk of thromboembolic complica-
tions include laparoscopic pelvic surgery, as well as 
long-duration of the surgery time (above 1 h) [92]. In 
addition, the presence of cancer, anticancer therapies 
and other VTE risk factor presence should be taken 
into consideration [9, 14, 92]. 
Due to a small number of studies focusing on the 
method and best possible timespan of thrombopro-
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phylaxis in patients undergoing laparoscopic oncologi-
cal surgeries, thus far it is only possible to extend the 
guidelines referring to the open surgeries. The benefits 
of prolonged antithrombotic prophylaxis at least in 
some patients undergoing laparoscopic oncological 
surgery are confirmed by Vedowatti et al. in the study 
conducted on 225 patients after laparoscopic colorec-
tal surgery (93). The patients were randomly assigned 
to the group with pharmacological VTE prophylaxis 
administered for 8 ± 2 days or to the group, where 
prophylaxis was prolonged to 4 weeks. The effective-
ness of prevention was checked by venous ultrasound 
imaging. No statistically significant differences were 
found in the incidence of bleeding complications. 
However, prolongation of antithrombotic prophylaxis 
up to 4 weeks significantly reduced DVT rate detected 
by the means of ultrasound (DVT rates: 9.7% in the 
short-term prophylaxis group vs. 0% in the long-term 
prophylaxis group) [93]. 
Guidelines
Venous thromboembolism prophylaxis  
in cancer patients undergoing  
surgical procedures
Guideline 2.1
The VTE risk as well as the risk of hemorrhagic 
complications should be individually assessed in each 
patient undergoing cancer surgery [1A].
Guideline 2.2
All patients undergoing extensive oncological 
surgeries in the abdomen and pelvis should receive 
VTE prophylaxis with prophylactic doses of low- 
-molecular-weight heparin or low doses of unfrac-
tionated heparin (3 × 5000 U), if there are no contra-
indications, including active bleeding or high risk of 
bleeding events [1A].
Guideline 2.3
Patients suffering from active cancer and at high 
risk of VTE undergoing other surgeries, who are not 
at high risk of serious bleeding complications, should 
receive pharmacological prophylaxis with low-mo-
lecular-weight heparin in the dose that is adequate to 
the VTE risk or low doses of unfractionated heparin 
(5000 U every 8 h s.c.) [1A].
Guideline 2.4
If bleeding risk is not high in cancer patients with 
moderate VTE risk undergoing other surgical proce-
dures than extensive surgery, it is recommended to 
administer thromboprophylaxis with low-molecu - 
lar-weight heparin or low doses of unfractionated hep-
arin according to the current risk assessment for VTE 
and up-to-date drug authorizations [1B].
Guideline 2.5
It is suggested that in cancer patients qualified for 
surgery, who are at high or very high risk of venous 
thromboembolism, pharmacological prevention should 
be supported with mechanical methods, most prefera-
bly intermittent pneumatic compression [2C].
Guideline 2.6
It is not recommended to use mechanical methods 
as the only prevention for thromboembolism (without 
pharmacotherapy) in surgical cancer patients, who are 
not at higher risk of bleeding [1B].
Guideline 2.7
In surgical patients at high risk of serious bleeding 
complications or in patients with contraindications for 
pharmacological prophylaxis due to active bleeding and 
high risk of bleeding relapse, mechanical prophylaxis 
should be considered (most preferably intermittent 
pneumatic compression), at least until the bleeding 
risk decreases and administration of pharmacological 
prophylaxis is possible [2C].
Guideline 2.8
In patients undergoing cancer surgery VTE proph-
ylaxis should be continued for a minimum of 7–10 
days [2B]. Patients undergoing major cancer surgery in 
the abdominal cavity and/or pelvis, who are not at high 
risk of serious bleeding complications and have VTE risk 
factors such as prolonged immobilization, obesity, histo-
ry of VTE, or other DVT risk factors, are recommended 
to receive prolonged pharmacological prophylaxis 
(4 weeks) with low-molecular-weight heparin [2B]. In 
the other cases, the decision regarding prolongation 
of prophylaxis should be made individually based on 
benefits and risk of such treatment [2C].
Guideline 2.9
In laparoscopic cancer surgery performed within 
the abdomen and pelvis it is suggested to assess the 
risk of VTE individually [1A] as well as to use the same 
principles of thromboprophylaxis as in patients oper-
ated by the means of laparotomy performed because 
of cancer [2C]. 
Guideline 2.10
Cancer patients who are at high risk of thrombo-
embolic complications and undergo surgery should not 
undergo inferior vena cava filter placement for primary 
antithrombotic prevention [2C].
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Chapter 3. Specific guidelines regarding 
cancer patients in selected surgical fields
Guidelines presented in Chapter 2 are dedicated 
to oncological surgical patients and contain the rules of 
prophylaxis in oncological surgery. For practical imple-
mentation of the proposed guidelines, it is necessary 
to take into account the characteristics of the treated 
patient population and the differences arising from the 
different bleeding risk, as well as the type of procedures 
performed. In order to provide guidelines in the most 
practical option, the authors analyzed recommenda-
tions available in the literature and proposed detailed 
guidelines for patients undergoing cancer surgery in the 
chosen surgical specialities such as: thoracic surgery, 
gynecology, neurosurgery, and urology.
3.1. VTE prophylaxis in patients  
undergoing thoracic cancer surgery
Lung cancer is associated with a high risk of throm-
boembolic complications. Patients undergoing major 
thoracic surgery because of cancer (including extensive 
lung resection, pneumonectomy, resection of the lung 
and pleura, or esophageal oncological resection) should 
be classified as at high risk of VTE [14, 94–97]. On the 
other hand, due to the still limited number and quality of 
available studies, data on the efficacy and risk of throm-
boprophylaxis in patients undergoing thoracic surgery 
is limited, and therefore formulated recommendations 
are based largely on reports relating to general surgery 
procedures [14, 15].
In studies based on retrospective assessment of 
VTE incidence, clinically symptomatic venous throm-
boembolism was found in 1.2–5.2% of patients un-
dergoing thoracic surgery and the incidence of VTE 
was higher in patients with lung cancer [94, 95]. In the 
study performed by Dentali et al. on 693 patients, who 
underwent thoracotomy due to lung cancer, despite 
the routine use of prophylaxis with LMWH or LDUH, 
symptomatic VTE was diagnosed in 1.7% of patients, 
including pulmonary embolism in 1.3% of patients, and 
fatal pulmonary embolism in 0.6% [98]. Kalweit et al. 
in the study evaluating the results of treatment of 1735 
patients, who underwent oncological lung resections, 
fatal pulmonary embolism was diagnosed post mortem 
in 1.2% of patients (despite the use of thromboprophy-
laxis in the majority of the studied population) [99]. 
Similar data was obtained in another retrospective 
analysis, in which the risk of clinically symptomatic VTE 
within 3 months in 13 000 patients undergoing major 
lung resections due to cancer amounted to 1.6% [100].
The incidence of VTE in the prospective studies 
evaluating VTE occurrence after cancer thoracic surgery 
appears to be significantly higher [14, 95, 101, 102]. 
Hachey et al. reported 5.2% of the cases of diagnosed 
VTE in patients undergoing thoracic surgery due to lung 
cancer within 60 days after operation, 1/3 of whom was 
diagnosed after discharge [103]. In a prospective clinical 
study conducted on 336 patients after pneumonectomy 
due to cancer, the risk of symptomatic VTE amounted 
to 7.4% despite the use of thromboprophylaxis with 
low-dose unfractionated heparin, as well as intermit-
tent pneumatic compression [104]. Weder et al. in the 
study evaluating outcomes of 176 pneumonectomies 
performed due to lung cancer conducted after preop-
erative chemotherapy found a mortality rate of 3%, half 
of which was associated with the pulmonary embolism 
occurrence [102]. In their research Schugarbecker et al. 
evaluated the results of surgical treatment of 328 pa- 
tients with pleural mesothelioma. Symptomatic VTE 
occurred within the first month after surgery in 7.9% 
of patients, whereas fatal pulmonary embolism in 1.2% 
of cases [104]. 
In the systematic review evaluating the results of 
19 studies, which included 10 660 patients undergoing 
thoracic surgery because of lung cancer, the incidence 
of VTE amounted to 2.0% (range 0.2–19%) [105]. In 
a retrospective analysis performed in 2013, which includ-
ed 6004 patients undergoing elective thoracic surgery 
in the context of pharmacological thromboprophylaxis 
based on VTE risk assessment, Gómez-Hernández et al. 
found that VTE occurred in 0.18% of cases. However, 
in this study only part of the patients were qualified for 
surgery due to cancer, and the risk of symtomatic VTE 
after pneumonectomy was significantly higher than in 
less extensive operations and amounted to 1.31% [106].
Like in other medical fields more extensive thoracic 
surgery generates higher risk of thrombotic complica-
tions. According to Swiniarska et al. pneumonectomy 
involves both, a significantly higher risk of VTE and 
stronger activation of the coagulation system than in 
lobectomy performed due to lung cancer at stage 1 
and 2 [107]. The following specific risk factors that 
increase the risk of VTE are important in this patient 
group: the very presence of cancer and the type as 
well as the grade of the tumor, non-radical resection of 
the tumor, postoperative use of anti-angiogenic agents, 
small-molecule inhibitors, tyrosine kinase inhibitors, 
EGFR and preoperative increase in D — dimer levels 
[108]. Other important risk factors in the lung cancer 
patients are radiotherapy and chemotherapy.  Kodlec et 
al. in the population of 950 patients suffering from lung 
cancer found VTE in 17.6% of cases in the group of sur-
gical patients and 11% and 48% of VTE cases in patients 
undergoing radio- and chemotherapy respectively [109].
Compared to studies relating to the symptomatic 
VTE, the percentage of asymptomatic VTE patients 
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qualified for extensive thoracic surgery, including cancer 
thoracic surgery, is significantly higher [110–114]. Based 
on the fibrinogen uptake test a high rate of DVT cases 
was reported (18–51%) in patients undergoing lobec-
tomy or pneumonectomy without thromboprophy- 
laxis [114]. Slightly lower values of asymptomatic DVT 
incidence were found in the ultrasound based studies 
in the thoracotomy patients (4–14%) [114].
In the evaluation of the risk and benefits of thrombo-
prophylaxis, bleeding risk should be assessed [14]. In the 
analysis of the large population concerning almost 17 000 
patients undergoing lung resection, the need for reopera-
tion due to bleeding complications was 1%, with a signifi-
cantly higher incidence of reoperation in the group of over 
1200 patients undergoing pneumonectomys (5%) [115].
There is limited data related to the prospective ran-
domized clinical studies on the use of pharmacological 
thromboprophylaxis in cancer thoracic surgery [112, 
113, 116–118]. Di Nisio et al. evaluated the safety and 
efficacy of primary thromboprophylaxis in patients after 
thoracic surgery, based on the analysis of the available 
prospective studies in the field of thoracic surgery. 
It should be pointed out that the studied groups of 
patients in particular clinical trials included only some 
patients diagnosed with cancer, and differed between 
each other, in terms of both, indications for surgery 
as well as the extensity of surgery performed [118]. In 
6 clinical trials evaluating the efficacy of pharmacological 
thromboprophylaxis 15 cases of pulmonary embolism 
were identified among 2890 surgical patients (0.51%). 
In this analysis, bleeding complications were observed 
after administration of low-molecular-weight heparin 
(LMWH at constant doses vs. LMWH doses adjusted 
to the weight — bleeding rate: 2.7% vs. 8.1% RR 0.33; 
95% CI: 0.07–1.60) as well as after application of LDUH 
(bleeding rate — 6%) [118]. Based on the above analysis, 
the authors formulated conclusions suggesting a need for 
individual evaluation of both, the risks of thromboembolic 
complications and bleeding complications in each patient 
eligible for thoracic surgery. 
Guidelines
VTE prophylaxis in patients undergoing 
thoracic cancer surgery
Guideline 3.1.1
In all patients undergoing thoracic surgery due to 
cancer, individual assessment of VTE risk as well as 
bleeding risk is recommended [1A].
Guideline 3.1.2
In the case of high risk of VTE and when there is low 
high risk of serious bleeding complications in patients 
undergoing thoracic cancer surgery, it is recommended 
to use LMWH [1B] or LDUH [1B] more than not using 
any pharmacological prophylaxis at all. At the same 
time, in patients at high and very high risk of VTE it 
is suggested to support pharmacological prophylaxis 
with mechanical methods (most preferably intermittent 
pneumatic compression — IPC) [2C].
Guideline 3.1.3
In cases of moderate risk of VTE and when there is 
no high risk of serious bleeding complications in cancer 
patients undergoing thoracic surgery, it is recommend-
ed to use LMWH [2B], LDUH [2B] or mechanical 
methods (most preferably intermittent pneumatic 
compression — IPC) [2C] more than not using any 
prophylaxis at all.
Guideline 3.1.4 
Patients undergoing thoracic surgery due to cancer 
who are at high risk of both VTE and bleeding complica-
tions, should be the candidates for mechanical methods 
of prophylaxis (preferably with the use of intermittent 
pneumatic compression — IPC), at least until the risk 
of bleeding decreases so that it is possible to start 
pharmacological prophylaxis [2C].
3.2. Thromboprophylaxis in patients un-
dergoing gynecological cancer surgery 
The incidence of deep venous thrombosis and 
pulmonary embolism after major gynecological sur-
gery corresponds with the one observed in patients 
undergoing general surgery, and the presence of cancer 
significantly increases the risk of VTE in this group of 
patients [14, 15, 114]. Clinical trials on gynecological 
surgery performed due to cancer suggest that the 
incidence of VTE ranges from 0 to 14.8% of women, 
who used different forms of thromboprophylaxis, up 
to over 35% in patients without prophylaxis [119]. The 
incidence of symptomatic VTE is significantly different 
in the studied populations, depending on the indications 
for surgical treatment as well as the extent and method 
of operation. Minimally invasive laparoscopic proce-
dures are associated with a significantly lower risk of 
VTE than the extensive oncological surgeries performed 
in highly thrombogenic cancers such as ovarian cancer 
[120–123]. In a large group of 4158 patients underwent 
gynecological cancer surgery the tumor most commonly 
associated with VTE occurrence was ovarian can- 
cer [124]. This is also confirmed by other reports that 
suggest a high incidence of VTE in the course of ovarian 
cancer and that a significant number of thromboembolic 
events in this type of cancer occur even before cancer 
is diagnosed and in as many as 4.8–20% of patients at 
the time of diagnosis [125–127].
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Despite growing awareness of VTE incidence in 
a population of patients undergoing gynecological cancer 
surgery, the number and quality of randomized clinical 
trials dedicated to this group of patients remains limited 
[14, 128–133]. Because there is still a small number 
of randomized studies conducted on patients, who 
underwent gynecological surgery, in particular, cancer 
surgery, the current recommendations in gynecological 
surgery are largely based on extrapolation of guidelines 
for patients undergoing general surgery [14, 15].
Taking into account the characteristics of this medical 
field, the relevant risk factors should additionally include, 
aside from the ones generally accepted for surgical pa-
tients, an abdominal access in comparison to transvaginal 
access, treatment extended to pelvic lymphadenectomy 
as well as earlier irradiation of this area. Hormonal ther-
apy may also be important in terms of an increased VTE 
risk. Other factors such as age, obesity, blood transfu-
sions or previous VTE episodes correspond with the risk 
factors found in surgical patients [14].
In available randomized trials a significant reduction 
of deep venous thrombosis incidence in major gyneco-
logical surgery was documented as a result of low-dose 
unfractionated heparin use [133]. However, only some 
of the patients taking part in the research included 
above were operated due to oncological reasons. In 
studies comparing the efficacy of low-dose unfraction-
ated heparin and prophylactic doses of low molecular 
weight heparin in gynecologic oncology surgery, there 
were no significant differences in both, the occurrence 
of VTE, as well as the percentage of bleeding, between 
the two methods of prophylaxis [68, 134–137]. 
Although a relatively smaller rate of thromboem-
bolic complications is reported in minimally invasive 
surgery, data on the effectiveness of VTE prevention in 
case of gynecologic laparoscopic procedures performed 
due to oncological reasons remains extremely limited 
and does not allow, at present, to define separate rules 
for the prophylaxis in laparoscopic surgery for this 
condition [137–140].
In a systematic review of literature, 11 randomized 
clinicaltrials related to the use of low molecular weight 
heparin and intermittent pneumatic compression in 
gynecologic cancer surgery were identified [141]. In the 
analysis of the studies on the effectiveness of the low-
-dose unfractionated heparin, a significant decrease in 
the incidence of DVT in the comparison to the control 
group (RR = 0.58, 95% CI 0.35–0.95) in this clinical 
settings was reported. In a group of 340 patients in 
which the efficacy of low-dose unfractionated heparin 
and low-molecular-weight heparin in this indication 
was compared, no significant differences in DVT oc-
currence between the two groups was noticed [141]. 
It should be emphasized that, the use of heparin in the 
prevention of cancer patients undergoing gynecolog-
ical surgery has proven more effective when applied 
in three subcutaneous injections than its usage twice 
a day [131, 142, 143]. 
Similar to general surgery patient population, there 
are also reports suggesting a high efficacy of intermit-
tent pneumatic compression in patients referred to 
gynecological cancer surgery [14, 143, 144]. Research 
conducted by Maxwell et al. related to 211 patients 
undergoing gynecological cancer surgery compared the 
results of thromboprophylaxis by the means of LMWH 
and IPC — in both groups no cases of symptomatic VTE 
and only 3 cases of asymptomatic ultrasonographically 
proven proximal DVT cases (in examination performed 
3–5 days after surgery) were found [145].
Data justifying extending the duration of throm-
boprophylaxis in cancer patients suggests a benefi-
cial effect of extending prophylaxis with LMWH in 
patients undergoing extensive oncological surgery 
in the abdomen and pelvic area without a significant 
increase in risk of bleeding [14]. So far, in the studies 
on this issue, gynecology patients operated because of 
oncologic indications were only a small percentage of 
the overall studied group (ENOXACAN II — 8% of 
the 332 randomized patients) and potentially available 
recommendations for this group of patients are based 
on guidelines for surgical patients [78].
The fact that a limited number and the low quality 
of research on gynecological surgery including cancer 
surgery is mentioned in ACCP 2012 guidelines, the 
common recommendations for patients undergoing 
surgical and gynecological treatment are proposed [14]. 
The authors having noticed this problem see the need 
for further research dedicated to oncological patients 
operated due to gynecological indications.
Guidelines
VTE prophylaxis in gynecological  
cancer surgery 
Guideline 3.2.1
In all patients undergoing gynecological cancer 
surgery, individual assessment of VTE risk as well as 
bleeding risk is recommended [1A].
Guideline 3.2.2
In cancer patients undergoing major oncological sur-
gery due to gynecological indications in the area of the 
pelvis and abdominal cavity, VTE thromboprophylaxis 
with prophylactic doses of low molecular heparin or low 
doses of unfractionated heparin is recomended, as long 
as there are no contraindications which include active 
bleeding or a high risk of bleeding complications [1A]. 
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Guideline 3.2.3
Unless there is a high risk of serious bleeding com-
plications in patients with cancer and a moderate risk 
of venous thromboembolism undergoing surgery other 
than major surgery it is recommended to administer 
VTE prophylaxis by the means of low-molecular-weight 
heparin or low doses of unfractionated heparin accord-
ing to the current VTE risk assessment evaluation [1B].
Guideline 3.2.4
In cancer patients qualified for surgery who are at 
high or very high risk of VTE it is suggested to support 
pharmacological prophylaxis with mechanical methods 
— most preferably with the use of intermittent pneu-
matic compression [2C].
Guideline 3.2.5
In patients undergoing gynecological cancer surgery 
who are at high risk of serious bleeding complications 
or in those patients who have contraindications to ad-
minister pharmacoprophylaxis due to active bleeding or 
high risk of bleeding recurrence, mechanical prevention, 
most preferably by the means of intermittent pneumatic 
compression should be considered at least until the 
risk of bleeding is reduced and start of pharmacological 
prophylaxis is possible [2C].
Guideline 3.2.6
In patients undergoing cancer gynecological surgery 
VTE prophylaxis should be continued for at least 7–10 
days [2B]. In patients undergoing major gynecological 
cancer surgery, who are not at a high risk of serious 
bleeding complications with the presence of VTE risk 
factors such as prolonged immobilization, obesity, history 
of previous VTE or other thrombosis risk factors, it is 
suggested to use the prolonged pharmacological prophy-
laxis (4 weeks) with low molecular weight heparin. [2C] 
In all other cases the decision concerning the extended 
of the prophylaxis duration prevention must be taken 
individually while assessing the risk/benefits ratio [2C].
Guideline 3.2.7
In the case of gynecologic laparoscopic cancer sur-
gery it is suggested to perform an individual VTE risk 
assessment [1A] as well as to use the same patterns 
of thromboprophylaxis as in the patients undergoing 
laparotomy due to cancer indications [2C].
Guideline 3.2.8
Gynecological cancer patients undergoing surgery, 
who are at a high risk of thromboembolic complications 
should not undergo inferior vena cava filter placement 
for primary antithrombotic prevention [2C].
3.3. VTE prophylaxis in neurosurgical 
cancer patients
Venous thromboembolism is one of the most 
significant complications in the population of the neu-
rosurgical cancer patients and its prevalence is related 
to the type of performed surgery, perioperative im-
mobilization and the tumor itself [14, 146–149]. Both, 
intra-cranial surgery and a malignant tumor presence 
significantly increase the risk of local bleeding compli-
cations [14, 150, 151].
Studies of limited quality on antithrombotic prophy-
laxis in the field of cancer neurosurgery indicate that 
the risk for venous thromboembolism is high when no 
prophylaxis is administered [150–152]. 
Available studies on thrombosis prophylaxis in neu-
rosurgery suggest the possibility to reduce the VTE risk 
effectively by the means of mechanical methods, as well 
as pharmacological prophylaxis [150–152]. However, 
most of these reports apply to the patients operated not 
only due to cancer. Prospective trials on effectiveness 
and safety of thrombosis prophylaxis in the oncological 
patient population undergoing neurosurgery are still 
very rare [150].
Studies on patients, who did not receive anithrom-
botic prophylaxis proved that craniotomy due to the tu-
mor presence corresponds with a risk for symptomatic 
VTE of, at least, 10%, which qualifies them as at a very 
high risk for thromboembolic events [14]. Smith et al. in 
a retrospective analysis of 1148 neurosurgical resections 
performed due to intracranial tumors estimated the 
DVT incidence at 13.7% and pulmonary embolism at 
3.3% [153]. The team working in the same health care 
facility analyzed also the results of surgical treatment in 
336 patients with malignant glioma and reported VTE 
incidence at 15.7% [154].
 According to the literature, VTE risk in patients 
suffering from malignant glioma is exceptionally high 
in subjects, who underwent craniotomy and surgical 
treatment, ranging from 21 to 32%, whereas deep ve-
nous thrombosis occurs in 3–25% of cases [155–161].
Most studies focusing on thrombosis prophy-
laxis analyze heterogeneous groups of neurosurgical 
patients, among whom only some suffered from 
a malignant tumor of the central nervous system. The 
report based on the analysis of 200 neurosurgical 
patients estimated the average risk of symptomatic 
VTE within 30 days of follow-up examination at 3.9%. 
However, the risk was significantly higher in patients, 
who underwent craniotomy due to a primary brain 
tumor (7.5%) or brain metastases 19%. In this study 
67% of the patients received antithrombotic prophy-
laxis [162].
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It should be emphasized that craniotomy patients, 
who were not diagnosed with a tumor, are also at 
high risk of VTE, and the VTE risk does not only cor-
respond with the type of surgery performed but also 
with concomitant risk factor presence [14]. Besides 
the very presence of the tumor, VTE risk factors in 
patients who undergo craniotomy due to the oncolog-
ical reasons, include: the type and stage of the cancer, 
advanced age, long surgery duration, non-radical tumor 
resection, prolonged immobility, paresis of limb/limbs, 
chemotherapy, corticosteroid administration, and the 
presence of central catheters [14, 155, 159, 160, 163]. 
Kimmel et al. specified the following VTE risk factors in 
patients undergoing craniotomy (in their study 56% of 
3098 patients underwent craniotomy due to mailgnancy): 
poor functional performance, age > 60 years, surgery 
duration > 4 hours, and postoperative complications 
such as: pneumonia, cerebrovascular events, sepsis, sep-
tic shock, unplanned and/or prolonged intubation [164].
Administration of appropriate prophylaxis for VTE 
prevention in neurosurgical patients, including those 
who were operated because of a tumor, requires an 
individual bleeding risk assessment in the context of 
disease etiology, projected surgery, and particular 
VTE prevention method. Postoperative intracranial 
bleeding requires further consideration. The review of 
20 studies performed on 31,000 craniotomy patients 
at total, who did not receive VTE prophylaxis suggests 
that the risk of intracranial bleeding amounts on aver-
age to 1.1%, however. the differences are significant 
depending, among others, on what the indication for 
surgery was [151]. 
Application of mechanical methods of VTE pro-
phylaxis in neurosurgical patients is a focus of interest, 
especially for procedures having a high bleeding risk, 
including neurosurgical oncological procedures [14, 
150, 151]. Apart from early patient mobilization, 
which is not always possible, mechanical methods of 
prophylaxis available for this group include intermittent 
pneumatic compression (IPC), graduated compression 
stocking, and electric calf muscle stimulation. In two 
trials, the effectiveness of IPC was compared with con-
trols, who did not receive any prophylaxis. The studies 
proved that IPC is beneficial for neurosurgical patients 
[165, 166]. Turpie et al. compared the effectiveness of 
IPC with the absence of any prophylaxis in the group 
of patients, among whom 51% suffered from a brain 
tumor [165]. Based on the fibrinogen uptake test, the 
authors found that deep venous thrombosis dropped 
from 23.5% to 1.5%. Skilman et al. studied the effec-
tiveness of antithrombotic prophylaxis in patients 69% 
of whom suffered from brain tumors. They observed 
a reduction in VTE incidence in patients who received 
IPC treatment from 25% to 8.3% [166].
Graduated compression stockings are usually more 
commonly used for VTE mechanical prophylaxis than 
IPC because of many reasons, including economic ones. 
However, data regarding their effectiveness, when used 
as a single prevention method in patients undergoing 
oncological neurosurgical procedures are limited and 
controversial. Bucci et al. in a study conducted on 
a small group of neurosurgical patients, among whom 
56% suffered from brain tumors, did not find any 
significant difference in the incidence of sympto-
matic deep venous thrombosis between patients using 
intermittent pneumatic compression and those using 
gradated compression stockings [167]. Angelli et al. 
conducted a study comparing outcomes of graduated 
compression stockings used along with enoxaparin and 
graduated compression stockings used with placebo. In 
the research arm where only compression stockings 
were used, the thrombosis incidence amounted to 
33% (evaluation based on phlebography) [168]. In this 
trial, opposed to the previous one, patients with brain 
or spinal cord tumors constituted 97% of analyzed 
population. The study conducted by Turpie et al. on 
the incidence of asymptomatic deep venous thrombosis 
also confirmed that differences in characteristics and 
risk rates between analyzed neurosurgical patient pop-
ulations are significant [169]. Deep venous thrombosis 
was diagnosed in 8.75% of patients using graduated 
compression stockings (in patients without prophylaxis 
the incidence amounted to 20%). However, only 48% 
of patients in this study were operated due to a brain 
tumor (and only some patients suffered from malignant 
brain tumors). Although this study revealed a decrease 
in VTE incidence, when graduated compression stock-
ings as well as complex prophylaxis with graduated 
compression stockings combined with intermittent 
pneumatic compression were used, there was no 
statistically significant difference between groups, in 
which mechanical prophylaxis was applied. Therefore, 
further studies are required in order to evaluate the 
role and efficacy of graduated compression stockings in 
neurosurgical patients and to directly compare the ef-
fectiveness of IPC with graudated compression stocking 
application [169]. In the study conducted by Wautrecht 
et al. on a small group, none of the 18 neurosurgical 
patients (100% of enrolled subjects suffered from 
a brain tumor), who received intermittent pneumatic 
compression combined with compression stockings 
developed DVT, whereas 2 of 5 patients, who used 
compression stockings only, developed deep venous 
thrombosis [170].
Recently, there is increased interest in other meth-
ods of mechanical prophylaxis such as electrical calf 
stimulation (ECF). The study conducted in order to as-
sess the effectiveness of ECF in high-risk neurosurgical 
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patients found that deep venous thrombosis incidence 
dropped from 18.7% to 4%, including proximal deep 
vein thrombosis rate decrease from 8% to 2.7%, and 
symptomatic DVT reduction from 2.7% to 0% [171].
Pharmacological prophylaxis in patients at a high 
and very high risk of VTE, especially those combining 
pharmacological prophylaxis with mechanical methods, 
potentially reduces the thromboembolic complication 
incidence in other medical fields [14]. Due to charac-
teristics of neurosurgical patients operated on account 
of oncological reasons and a potential neurosurgery as 
well as pharmacological prophylaxis related bleeding 
risk, this subject requires further studies also in the field 
of the cancer neurosurgical treatment. Meta-analysis of 
4 randomized controlled clinical trials on pharmacological 
prophylaxis for thrombosis prevention in neurosurgery 
(three of them involving antithrombotic prophylaxis 
with low-molecular-weight heparin and one of them 
low doses of unfractionated heparin, with or without 
mechanical prophylaxis methods proved that DVT 
incidence dropped from 29% in controls to 16.1% in 
patients, who received pharmacological prophylaxis 
(proximal DVT incidence dropped from 12.5 % to 
6.25%). Regarding the hemorrhagic complications, at 
the time, the risk of “major” bleedings increased from 
2.5% to 3.1%, and the overall bleeding incidence in-
creased from 2.9% to 5.9% [172]. 
The timing of the antithrombotic pharmacological 
prophylaxis administration plays an important role in 
neurosurgical patients. Due to the fact that most of the 
intracranial bleedings in neurosurgical patients occur 
within the first 12–24 hours after craniotomy, and half 
of thromboembolic events occur later (after the first 
week after surgery), in patients at a high risk of VTE, 
it is justified to start VTE pharmacological prophylaxis 
postoperatively (after obtaining proper hemostasis) 
[146, 160].
Dickinson et al. conducted a study on patients with 
brain tumors and attempted to compare effectiveness 
of antithrombotic prophylaxis in 3 groups of patients, 
who received intermittent pneumatic compression, 
LMWH (enoxaparin) and combination therapy with two 
of the aforementioned methods. In this study, LMWH 
was administered before surgery. The trial was discon-
tinued due to a high bleeding rate in patients where 
pharmacological prophylaxis was administered before 
surgery (the hemorrhagic events occurred mostly in 
an early postoperative period and 3 patients required 
surgical reintervention). The authors suggest that pa-
tients receiving low-molecular-weight heparin should 
undergo intracranial procedures no sooner than after 
an appropriate time after the last dose of LMWH [173]. 
Agnelli and Nurmohamad evaluated effectiveness and 
safety of LMWH at prophylactic dose administered with 
the first 24 hours after surgery (LMWH + graduated 
compression stockings vs. LMWH) [168, 174]. In the 
first trial, DVT and proximal DVT incidence amounted 
to 33% and 13% respectively in the group of patients, 
who used only graduated compression stockings in 
comparison to 17% and 5% in the group, who received 
combined prophylaxis [168]. In the second trial, the 
incidence amounted to 26% and 12% respectively 
in patients using only compression, and 19% and 7% 
for combination of mechanical and pharmacological 
prophylaxis (with LMWH prophylaxis started postop-
eratively).
Also in phlebography based studies, a drop in inci-
dence of proximal deep venous thrombosis from 28.9% 
to 17.9% was observed in patients, who received 
combination prophylaxis (along with a decrease in prox-
imal DVT rate from 12% to 5.7%, and an increase in 
incidence of “major” bleeding complications from 2.0% 
in patients receiving graduated compression to 3.4% in 
patients, who additionally received LMWH) [168, 174]. 
Effectiveness and safety of unfractionated heparin 
administered at low doses for pharmacological prophy-
laxis in neurosurgical patients, including a substantial 
number of patients operated on account of a brain tu-
mor, was also assessed. Unfortunately, the outcomes of 
these studies also raise doubts regarding especially the 
characteristics of the treated population. Cerrato et al. 
analyzed the effect of antithrombotic prophylaxis with 
low doses of unfractionated heparin (prophylaxis began 
before surgery) in a group of patients, 87% of whom 
were suffering from a brain tumor, and discovered 
a drop in incidence of asymptomatic VTE from 34% to 
6% [175]. Constatini et al. using a similar VTE prophy-
laxis algorithm did not observe “major” bleedings, 
however, at the same time did not report a decrease 
in incidence of symptomatic DVT in comparison to 
placebo [176]. Two other studies comparing prophy-
lactic administration of LMWH and LDUH combined 
with mechanical prophylaxis (63–93% of patients in 
this group suffered from a brain tumor) did not find 
significant differences in incidence of “major” bleedings 
between the groups [177, 178].
The analysis performed by Collen et al. on 18 ran- 
domized clinical trials and 12 prospective trials on ap-
plication of IPC, LMWH and low dose unfractionated 
heparin for thromboembolism prevention in neuro-
surgery confirms the effectiveness of both methods 
(mechanical prophylaxis — IPC and pharmacological 
prophylaxis — LMWH) [151]. Application of LMWH, as 
well as IPC, decreased the risk of DVT, simultaneously 
increasing the risk of minor bleedings, and increasing 
the incidence of the complex study end-point defined as 
“minor” bleeding occurrence and intracranial bleeding 
in the group of patients treated with LMWH [151].
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Meta-analysis conducted by Hamilton et al. com-
paring results of VTE prophylaxis in 1170 patients 
(6 randomized clinical trials on low dose unfractionated 
heparin or low-molecular-weight heparin administration 
in comparison to the controls not receiving pharma-
cological prophylaxis), who underwent neurosurgical 
operations within the skull, confirmed that prophylactic 
heparin doses reduce DVT incidence and, at the same 
time, increase the risk of intracranial bleeding [152]. 
Based on this analysis, pharmacological prophylaxis 
used in 1000 patients, who underwent craniotomy, 
will potentially prevent 91 venous thromboembolism 
events (including 35 proximal deep venous thrombosis 
or pulmonary embolism cases), and at the same time will 
put 7 patients at risk of intracranial bleeding, and 28 pa- 
tients at risk of “minor” bleeding complications [152]. 
The systematic review based on the treatment results of 
1932 patients, from which 1558 were operated on the 
account of a brain tumor should be also mentioned in the 
context of these guideline proposal [150]. The authors 
concluded that administration of mechanical prophylaxis 
before surgery and its continuation until discharge reduce 
the incidence of venous thromboembolism without an 
increase in bleeding risk. Administration of pharmaco-
logical prevention with LMWH further reduces VTE 
incidence and increases the risk for “major” bleeding 
complications [150]. Due to significant heterogenicity 
of analyzed populations, various prophylaxis regimens 
used as well as the differences in bleeding complication 
risk related to the type of procedure performed, there is 
a need for further research in order to define an optimal 
antithrombotic prevention method in patients undergo-
ing neurosurgical oncological procedures.
Guidelines 
VTE prophylaxis in neurosurgical  
cancer patients
Guideline 3.3.1
The risk for venous thromboembolism as well as for 
bleeding complications should be assessed individually 
for each patient undergoing neurosurgical oncological 
procedures [1A].
Guideline 3.3.2
Due to potential bleeding risks, patients undergoing 
intracranial oncological neurosurgery should receive 
mechanical prophylaxis for prevention of venous 
thromboembolism, most preferably by the means of 
intermittent pneumatic compression, in the perioper-
ative and postoperative period [2C]. 
Guideline 3.3.3
In patients undergoing intracranial oncological neu-
rosurgery related to high or very high risk of venous 
thromboembolism, who are not at high risk for bleed-
ing, in the postoperative period the pharmacological 
thromboprophylaxis by the means of low doses of un-
fractionated heparin or low molecular heparin should be 
added to the mechanical methods of prophylaxis [2C].
Guideline 3.3.4
In patients undergoing intracranial oncological neu-
rosurgery qualified for pharmacological antithrombotic 
prevention, the pharmacological prophylaxis should be 
started postoperatively, if proper hemostasis is achieved 
[2C]. The time, when pharmacological prophylaxis 
should begin must be assessed individually considering 
bleeding risk and local hemostasis [1C].
Guideline 3.3.5 
Patients undergoing intracranial oncological neu-
rosurgery should not undergo inferior vena cava filter 
placement for primary antithrombotic prevention [2C].
3.4. VTE prophylaxis in surgical  
urological cancer patients 
It is often difficult to estimate surgery-related bleed-
ing risk for the urinary tract. A limited number and 
quality of studies on this issue hinder elaboration of final 
guidelines on VTE prophylaxis in patients undergoing 
urologic oncological surgeries [14, 179]. Because of that 
fact, many up-to-date guidelines extrapolate results of 
the studies conducted on patients undergoing abdomi-
nal and pelvic surgery [14, 21, 23, 30]. Lack of research 
of sufficient quality hinders elaboration of guidelines 
dedicated to anti-thrombotic prophylaxis in the particu-
lar urologic procedures. Hitherto, such guidelines were 
formulated only by the American Urological Association 
as the Best Practice Statement in 2008 [180]. Although, 
this document determines cancer as a significant VTE 
risk factor, the AUA statement applies to patients un-
dergoing urological surgery because of various reasons, 
including cancer-unrelated ones [180].
The characteristics of urology itself, high percentage 
of endoscopic and laparoscopic procedures along with 
a high bleeding risk justify taking them into account in 
an elaboration of guidelines for antithrombotic prophy-
laxis and individual approach to each patient qualified 
to urologic oncological surgery. 
In extensive and open urologic oncological surgeries 
within the lesser pelvis (prostatectomy, cystectomy), 
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the VTE risk, when no prophylaxis is given, corresponds 
to the risk observed for extensive procedures in general 
surgery (VTE risk at 10–30%, pulmonary embolism 
risk at 1–10%) [14, 179, 181–183]. Symptomatic ve-
nous thromboembolism occurs on average in 1–5% of 
patients after extensive urologic surgeries within the 
pelvis [14]. This risk seems to be even higher in some 
extensive urologic intraabdominal oncological surger-
ies. Radical oncological cystectomy with ileal conduit 
urinary diversion is an example of such a procedure 
[14, 179, 184]. In the study published in 2015 based on 
retrospective analysis of 27,455 patients, who under-
went extensive urologic oncological surgeries, symp-
tomatic VTE was diagnosed in 2.93% of cases [185]. 
The highest incidence of symptomatic VTE within 
30 days after surgery was observed in patients after 
radical oncological cystectomy and amounted to 5.5% 
(there were no data available regarding antithrombotic 
prophylaxis), whereas the incidence amounted to only 
0.7% in patients, who underwent minimally invasive or 
partial nephrectomy due to cancer [185]. Similar data 
suggesting high percentage of VTE in patients under-
going radical cystectomy due to cancer can be found in 
other reports. Potretzke et al. detected symptomatic 
VTE in 8.3% of patients after radical oncological cys-
tectomy [186]. VanDlac and Rosario estimated in two 
independent trials that the risk for symptomatic VTE in 
patients after radical cystectomy amounts to 6% [187, 
189]. Based on treatment results of 1581 patients after 
radical cystectomy performed due to urinary bladder 
cancer, James reported that VTE occurred in 10% of 
the cases within 90 days after surgery [189].
Most of the available data concerning VTE risk and 
antithrombotic prophylaxis in patients undergoing 
urologic cancer surgery reffers to patients after radical 
prostatectomy. According to the reports published 
in recent years, estimated risk of symptomatic VTE 
ranges from 0.8% to 6.2% in patients, who under-
went open prostatectomy, whereas the risk of fatal 
pulmonary embolism amounts to 0.4–1.1% [190–199]. 
Dilioglugi et al. found that in the group of 472 patients 
after prostatectomy, 1.1% suffered from symptomatic 
pulmonary embolism and 1.3% from DVT [198]. 
Likewise, Andriole and Catalona based on treatment 
results of 1,000 patients after this kind of surgery esti-
mated the VTE incidence at 2.6% and 2% respectively 
[197, 200]. Hammond et al. analyzed 20,000 extensive 
oncological surgeries, including urological oncological 
surgery and found that symptomatic VTE occurred in 
1.8% of patients after prostatectomy [201]. In cases, 
where no prophylaxis was applied and thromboembolic 
complications were assessed by the means of imaging 
methods after prostatectomy, the risk seems to be 
significantly higher (16.8–32%), which results from high 
percentage of asymptomatic deep venous thrombosis 
cases [203–204]. 
Aside from the presence of cancer, significant 
risk factors in patients undergoing urologic surgeries 
include: advanced age, extensive pelvic surgeries, 
extensive retroperitoneal lymphadenectomy, litho-
tomy position, obesity, and hormonal therapy (e.g. 
anti-androgen treatment), and, as in other medical 
fields, clinically significant concomitant disease presence 
[14, 205–208]. The presence of cancer also increases 
the risk for symptomatic VTE occurrence after upper 
urinary tract surgeries up to 1–5% [14, 179, 12, 183]. 
California Patient Discharge Data Set retrospective 
analysis estimated the incidence of symptomatic VTE 
at 2% after nephrectomy preformed because of malig-
nancy [190]. Pettus et al. evaluated the VTE incidence in 
2208 patients after partial or radical nephrectomy (only 
mechanical methods of VTE prophylaxis were used) 
and estimated that symptomatic VTE occurred in 1.5% 
of patients and pulmonary embolism in 0.9% [209]. 
In case of renal cancer, risk factors for VTE compli- 
cations, aside from staging and the presence of metas-
tases, include: the presence of concomitant diseases, 
long surgery duration, non-radical operation, cancer 
infiltration into the renal vein and/or inferior caval 
vein [210–212].
Because of the development of laparoscopic tech-
niques, also in urology more and more procedures are 
performed by the means of minimally invasive surgery, 
such as robotic surgical systems. However, even these 
procedures, despite of significantly less severe surgical 
trauma and faster mobilization of the patient, are not 
free from thromboembolic complications. Incidence of 
VTE amounts to 0.13–4.8% of patients, who underwent 
urologic laparoscopic surgery, whereas incidence of pul-
monary embolism is estimated at 0.08–1% [213–220]. 
Chalmers et al. analyzed VTE incidence in 1486 patients 
after radical robotic prostatectomy and antithrombotic 
prophylaxis with intermittent pneumatic compression 
combined with low doses of unfractionated heparin or 
intermittent pneumatic compression prophylaxis only. 
In both groups the incidence of symptomatic VTE was 
comparable (1.0% vs. 0.7%) [221]. The other authors 
also report relatively low incidence of symptomatic 
VTE (0.5–0.6%) in laparoscopic or robotic prostatec-
tomy [220, 222]. On the other hand, some reports 
suggest higher risk for such complications despite 
of antithrombotic prophylaxis administration in this 
clinical settings. Abel et al. found that within 30 days 
after radical robotic prostatectomy, VTE occurred in 
1.8% of patients (despite of mechanical methods of 
antithrombotic prevention implementation as well as 
pharmacological prophylaxis with single heparin dose 
administered before surgery) [223]. The authors of this 
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study indicate that surgery duration is also important in 
the context of an increased VTE risk [223]. 
Urologic endoscopic procedures (transurethral uro-
logical surgery) are also not free from thromboembolic 
complications, although the incidence of symptomatic 
VTE is significantly lower in these kind of the proce-
dures (symptomatic VTE: 0.1–0.75%; PE 0.1–0.84%). 
The presence of cancer as well as other concomitant 
diseases may significantly increase the risk of DVT and 
PE in patients, who undergo transurethral procedures 
such as transurethral electro-resection of the prostate 
as well as resection of bladder cancer [14, 182, 190, 
224]. The analysis of extensive California Patient Dis-
charge Data Set assessed symptomatic VTE incidence 
at 0.3–0.5% in patients, who underwent transurethral 
resection of prostate adenoma within 3 months after 
surgery. On the other hand, according to White et al. 
the VTE incidence in patients after e.g. percutaneous 
nephrostomy performed due to cancer amounted to 
3.6% [190]. 
Clinical application of guidelines on antithrom-
botic prophylaxis, as well as progress in the surgical 
techniques resulting among others in the reduction of 
procedure duration, significantly decreased incidence 
of thromboembolic complications after extensive 
urologic surgeries [14, 179, 206]. On the other hand, 
application of minimally invasive techniques reduced 
incidence of thromboembolic complications but did not 
eliminate them entirely, whereas pulmonary embolism 
remained to be the most common nonsurgical cause of 
death in this group [14, 180]. Like in the other surgical 
specialties, assessment of VTE risk and bleeding risk is 
crucial for the proper qualification for antithrombotic 
prophylaxis [14, 180, 225]. Because of the fact that 
there are no studies referring to the particular clinical 
situations (the same type of surgery, same bleeding risk 
and VTE risk) of sufficient quality, individual approach 
and treatment in each patient is encouraged.
The number of prospective clinical trials on an-
tithrombotic prophylaxis in patients undergoing urologic 
surgery, including cancer surgery, is limited. Kutnowski 
and Sebseri report that the DVT incidence decreased 
after administration of low doses of unfractionated hep-
arin for VTE prophylaxis in patients undergoing urologic 
surgeries (from 36–58% to 9–12%) [226, 227]. Bigg et 
al. obtained similar results in the group of patients after 
open prostatectomy (PE: 0% vs. 11%) [228]; incidence 
of pulmonary embolism was significantly lower after 
prophylactic heparin administration. Vandendris used 
low doses of unfractionated heparin for prophylaxis in 
patients qualified for open prostatectomy and report-
ed a drop in deep venous thrombosis incidence from 
39.4% to 9.7% [229]. In a review of 7 prospective ran-
domized clinical trials on pharmacological anthrombotic 
prevention, Collins et al. documented a significant drop 
in DVT incidence accompanied by a significant increase 
in the risk of bleeding in patients receiving low doses 
of unfractionated heparin for prophylaxis (incidence of 
clinically significant bleeding complications ranged from: 
3.8% to 5.9%) [230].
By far there are no prospective randomized clinical 
trials of sufficient quality focusing on low-molecular-
-weight heparin administration for antithrombotic pre- 
vention in urologic cancer patients [231]. Studies on 
administration of LMWH for antithrombotic prophylaxis 
performed thus far in this group of patients are based 
on retrospective analyses or on prospective follow-up 
of the small patient groups. In the study conducted by 
Sawczuk on 38 patients qualified for elective urologic 
cancer surgery, dalteparin (2500 units s.c., prophylaxis 
began 1–2 hours before surgery) along with intermit-
tent pneumatic compression was used. Within 3–7 
days of thromboembolism prophylaxis, there was no 
symptomatic VTE episode diagnosed and at the same 
time, no excessive bleeding was observed [232]. Koch 
assessed the effectiveness of enoxaparin administered 
an hour before surgery at the dose of 30 mg (and next 
after 12 hours) in patients undergoing open prosta-
tectomy and did not report symptomatic VTE events 
in the group receiving prophylaxis, whereas 3.3% 
in the controls, who used only compression means, 
presented with thromboembolic events [233]. In this 
study, postoperative bleedings (7.8% vs. 0%) and lymph 
collection in the pelvis were diagnosed more often in 
patients receiving pharmacological prevention [233]. 
Information on potential influence of pharmacological 
prophylaxis on incidence of lymph collection after pelvic 
lymphadenectomy is also available in the other studies 
[234–237]. Boncinelli et al. compared the effective-
ness of treatment with nadroparin in the single daily 
dose of 0.3 mL with LDUH at the dose of 3 × 5000 U 
in 50 patients undergoing open prostatectomy in 
a prospective randomized clinical trial. In both groups 
neither symptomatic thromboembolic complications 
nor bleeding complications were observed [238]. 
Available studies also refer to postoperative anti-
thrombotic prophylaxis as one of the VTE prevention 
methods [239, 240]. Nakumara used enoxaparin at 
the dose of 40 mg (prophylaxis began 6–8 hours after 
surgery) in a group of 47 patients, who underwent 
open prostatectomy, and reported VTE incidence at 
4% [239]. Grasso et al. retrospectively analyzed 500 
patients after radical prostatectomy, who received 
hemodilution, compression stockings, and pharmaco-
logical prevention administered up to 24 hours after 
surgery and found only two VTE episodes as well as 
two bleeding complications that required surgical in-
tervention [240]. As for now there are no prospective 
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randomized trials on prophylaxis for thrombosis after 
transurethral oncological surgeries, whereas few avail-
able reports on VTE prevention mostly refer to the 
patients undergoing urological surgery due to other 
reasons. Retrospective analysis of 883 patients, who 
underwent transurethral radical prostatectomy (TURP) 
and used graduated compression stockings indicated 
that symptomatic pulmonary embolism occurred in 
0.45% of the patients [241]. In the @RISTOS study 
conducted on patients undergoing cancer urological 
surgery (mostly due to bladder and prostate carcinoma, 
61% of whom underwent laparoscopic surgeries) 
symptomatic VTE was found in 0.87% of patients, while 
71% of the patient population received prophylaxis 
during hospitalization, and in 32% of them prophylaxis 
was continued after discharge [242]. 
In endoscopic urologic surgeries as well as in open 
surgery, bleeding risk assessment is significant for the 
proper an safe thromboembolism prophylaxis imple-
mentation [225, 243]. In this context, in the patients 
with elevated bleeding risk mechanical prophylaxis 
methods, such as intermittent pneumatic compression 
are of special interest. According to the performed 
studies, intermittent pneumatic compression in patients 
undergoing open urologic surgeries causes a reduction 
in VTE incidence [244]. Koya found VTE incidents only 
in 0.21% of 1,364 patients undergoing radical prosta-
tectomy, who used early mobilization and intermittent 
pneumatic compression for thromboprophylaxis [245]. 
On the other hand Cisek et al. suggest that application 
of intermittent pneumatic compression in high-risk 
patients does not decrease the total VTE risk in this 
population, however does significantly delay thrombosis 
event occurrence (the average time for VTE diagnosis 
in this study amounted 3020 ± 2 days vs. 11 ± 5 days 
after surgery) [246]. In this group of patients (patients 
at high risk and very high risk for VTE), it seems reason-
able to use pharmacological prophylaxis or combination 
treatment instead of only mechanical methods of VTE 
prophylaxis [14, 180].
Alike in general surgery, combination of mechanical 
methods with pharmacological prevention reduces VTE 
risk, and it is more clinically effective than any of those 
methods used alone [88, 247]. By far, few studies on 
urological patients (including two randomized trials), 
did not prove the advantage of intermittent pneumatic 
compression over LDUH administration in this group 
of patients [248, 249]. Montgomery et al. conducted 
retrospective analysis of urological laparoscopic sur-
geries and compared effects of thromboprophylaxis 
with LDUH or intermittent pneumatic compression. 
The analyzed population included patients qualified for 
laparoscopic urologic surgeries (including 217 patients, 
who underwent nephrectomy). There were no signi-
ficant differences in VTE incidence between groups, 
however patients who received pharmacological pre-
vention showed bleeding complications more often 
(bleeding incidence 9.3% vs. 3.5%; major bleedings 
7.0% vs. 2.9%) [250]. In the aforementioned study con-
ducted on 5,951 patients undergoing either laparoscopic 
prostatectomy or robotic prostatectomy, 67% of the 
subjects received heparin in the perioperative period. 
In spite of a low VTE rate (0.5%) and pulmonary embo-
lism rate (0.2%) perioperative administration of LMWH 
was related to higher blood loss, longer hospitalization 
period, higher transfusion rate, and higher percentage 
of reoperations [219].
Due to limited invasiveness and often short duration 
of gradually more commonly performed laparoscopic 
surgeries (e.g. in the field of general surgery), up-to-date 
guidelines on laparoscopic surgeries do not encourage 
routine administration of pharmacological prophylaxis, 
permitting for early mobilization and mechanical meth-
ods implementation [14, 92, 180]. Other risk factors 
such as prolonged laparoscopic surgery, lesser pelvis 
surgery and cancer increase the risk, and according to 
the individual VTE and bleeding risk assessment, thus 
justifying the administration of prevention methods 
(including pharmacological prophylaxis). 
Like in other disciplines, the question of how long 
prophylaxis should last remains open. Based on ex-
trapolation of guidelines referring to surgical patients, 
it is reasonable to administer primarily prolonged 
thromboprophylaxis with low-molecular-weight hepa-
rin to the patient undergoing extensive surgery of the 
abdomen and pelvis, including cancer surgery [14]. 
Alberts et al. in the study referring to the analysis per-
formed by the National Surgical Quality Improvement 
Program in the USA between 2002 and 2012 empha-
size that, up to 82.6% of VTE events after radical 
prostatectomy were diagnosed after discharge [251]. 
Leibovitch et al. concluded in their study that 7 of 
9 cases of DVT diagnosed after radical retropubic pros-
tatectomy occurred after discharge [192]. VanDlac 
et al. reported that in a group of 1,307 patients after 
radical cystectomy, 55% of VTE events were diag-
nosed after discharge [252]. The study performed by 
Kukreja et al., is one of the few works on appropriate 
antithrombotic prophylaxis duration in urology [253]. 
The authors of this study compared outcomes of 
thromboprophylaxis in patients undergoing urologic 
cancer surgery in the context of prophylaxis duration 
(prophylaxis in the hospital vs prophylaxis for 28 days 
after surgery). In the group receiving prolonged pre-
vention VTE occurred in 7% of cases, whereas in 17% 
of patients, who received treatment in the hospital 
VTE was diagnosed; there were no differences in the 
bleeding rates between the groups [253]. 
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The authors of guidelines are aware of the fact that the 
quality and number of reports on thromboprophylaxis in 
patients undergoing urologic cancer  surgeries are limited, 
and  therefore suggest an individual VTE risk as well as 
risk of bleeding assessment. At the same time, due to low 
quality of most of the guidelines, the authors emphasize 
the need for further studies and potential modifications 
implemented based on results of these studies as well as 
for an individual approach to risk assessment for venous 
thromboembolism and bleeding in each case.
Guidelines 
VTE prophylaxis in urological patients 
operated due to cancer
Guideline 3.4.1
The risk of venous thromboembolism and of bleeding 
complications should be assessed individually for each 
patient undergoing urologic surgery due to cancer [1A].
Guideline 3.4.2
In patients undergoing major urological surgery due to 
cancer and in those undergoing other urological proce-
dures, who are at high risk of venous thromboembolism, 
it is recommended to consider the use of thromboprophy-
laxis based on LDUH [1B] or LMWH [1C], if the risk of 
bleeding do not significantly outstands potential benefits 
associated with the use of pharmacoprophylaxis. Due to 
the limited availability of research and the specificity of 
the treated population, the optimal moment of starting 
pharmacological prophylaxis in these patients has not 
been finaly defined and therefore should be based on 
individual evaluation of the benefits and risks of this type 
of prophylaxis [2C]. In case of a significant bleeding risk in 
the perioperative period, it is suggested to use mechanical 
methods of VTE prevention (most preferably intermittent 
pneumatic compression) [1C].
Guideline 3.4.3
In cancer patients with moderate VTE risk undergo-
ing other surgeries than major ones, it is recommended 
to decide about the method and the time for adminis-
tration of thromboprophylaxis according to present risk 
assessment for VTE and bleeding complications [2C].
Guideline 3.4.4
In patients undergoing urologic surgery due to can-
cer at high risk of venous thromboembolism and bleed-
ing complications, or in patients with contraindications 
for pharmacological prophylaxis, it is suggested to use 
mechanical prophylaxis, (most preferably intermittent 
pneumatic compression), at least until the bleeding 
risk decreases and administration of pharmacological 
prophylaxis becomes possible [2C].
Guideline 3.4.5
It is suggested that in cancer patients undergoing 
major urologic surgeries, qualified for pharmacological 
prophylaxis due to high or very high risk of venous 
thromboembolism, pharmacological prevention should 
be supported with mechanical methods (most prefera-
bly intermittent pneumatic compression) [2C].
Guideline 3.4.6
In patients undergoing major urologic surgeries in the 
abdominal cavity and/or pelvis, who are not at high risk of 
serious bleeding complications it is suggested to prolong 
pharmacological prophylaxis (4 weeks) with low-molecular-
-weight heparin [2C]. In the other cases, the decision 
regarding prolongation of prophylaxis should be made indi-
vidually based on benefits and risk of such treatment [2C].
Guideline 3.4.7
In laparoscopic cancer surgery it is suggested to as-
sess the risk of venous thromboembolism individually [1] 
as well as to use the same rules of thromboprophylaxis 
as in patients operated by the means of laparotomy 
performed due to cancer [2C]. 
Guideline 3.4.8
In patients undergoing transurethral and percutane-
ous endoscopic surgeries due to cancer it is suggested 
to assess the risk of venous thromboembolism and 
the risk of bleeding complications individually as well 
as to decide on prophylaxis administration based on 
evaluation of benefits and risks of such treatment [2C]. 
The decision on prophylaxis administration as well as 
the chosen prevention method, and the right time for 
its administration should be based on characteristics 
of the particular procedure and bleeding risk assessed 
individually in each case [2C]. In the case of high risk of 
bleeding, in the first place, early patient mobilization 
as well as mechanical prophylaxis should be used [2C], 
and pharmacological prophylaxis should be added, when 
hemostasis is satisfactory [2C].
Chapter 4. Prevention of venous  
thromboembolism in cancer patients  
ineligible for surgical treatment  
and treated in hospital settings
Cancer itself is an important risk factor for VTE not 
only in surgical patients, but also in those hospitalized on 
surgical and non-surgical wards and treated conservatively 
[4, 9, 23, 28, 32, 33, 254]. Because of the tumor, concom-
itant risk factors of VTE and factors relating to both pa-
tient’s condition and treatment itself, most cancer patients 
admitted to the hospital will require thromboprophylaxis 
adequate to the risk [15, 32, 33, 36, 38, 254]. Despite the 
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lack of qualifications for surgical treatment, cancer patients 
receiving conservative treatment in the hospital (also in 
surgical wards) are also at higher risk of VTE [15, 32, 36, 
254] (Table 2).
Cancer treatment, particularly chemotherapy and 
combination therapy including cytostatics, angiogenesis 
inhibitors or drugs that affect the hormonal status of the 
patient are considered to be a potential risk factor for 
VTE in hospitalized patients especially, when the patient’s 
mobility is limited in the hospital settings [32, 33, 36–38]. 
Nevertheless, the issue of routine thromboprophylaxis 
in hospitalized patients, who are undergoing diagnostics 
for cancer remains open. In these cases, the decision to 
implement pharmacological prophylaxis should be made, 
considering an individual assessment of the risk of VTE 
and the risk of bleeding complications associated with the 
treatment. 
Thus far, no prospective clinical trials were per-
formed on VTE prophylaxis for VTE specifically in the 
group of hospitalized cancer patients receiving conser-
vative treatment. However, these patients participated 
in the study on efficacy of pharmacological thrombo-
prophylaxis in the group with medical patients, who 
were immobilized in hospital with acute medical ilness 
as a part of the analyzed population (5–15%) [255–257]. 
The aforementioned studies dedicated to the medical 
patients proved the advantage of active pharmacological 
prophylaxis with low-molecular-weight heparin, low 
doses of unfractionated heparin, and fondaparinux over 
placebo [255–257]. A number of research on efficacy 
Table 2. The risk factors for venous thromboembolism, taking into account the characteristics of the cancer patient’s population 
[modified according to 15, 28]
Category Risk factor
Risk factors depend on the patient 
and comorbidity 
Age (> 40) 
A positive family history
Obesity
Trauma (in particular polytrauma, pelvic fractures, fractures of long bones 
of the lower limb)
Cerebrovascular events with paresis or mobility restriction
Sepsis
Acute infection
Heart failure NYHA III and IV
A history of myocardial infarction 
Respiratory failure (especially exacerbation)
Autoimmune diseases
Nephrotic syndrome
Myeloproliferative syndrome
Paroxysmal nocturnal hemoglobinuria
Vein compression 
Pregnancy and postpartum
Vein varicose in lower limbs
History of venous thromboembolism 
Thrombophilia 
Long-term immobilization (in hospital, at home, or due to traveling)
Risk factors depend on the type 
and stage of cancer
Tumor location
Staging (risk increases along with staging)
Type of cancer (pathological result) 
Time after diagnosis (increase in the first 3–6 months and in advanced cases)
Risk factors depend on therapy Surgical treatment
Prolonged postoperative immobilization 
Chemotherapy
Hormone therapy, HRT, use of selective estrogen receptor modulators 
Radiotherapy
Transfusions of packed red blood cells, plasma
Administration of erythropoesis stimulating factors 
Administration of angiogenesis inhibitors
Central catheters, ports
Leukocytosis (above 11 × 109/L)
Anemia-hemoglobin < 100 g/L
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of low-molecular-weight heparin and unfractionated 
heparin in patients admitted to the hospital on account 
of acute internal disease showed that LMWH presents 
at least comparable effectiveness [258–264]. 
Based on the results of the aforementioned studies, 
most guidelines available thus far recommend admini- 
stration of thromboprophylaxis with low-molecular- 
-weight heparin, unfractionated heparin, or fondaparinux 
in hospitalized patients receiving conservative treat-
ment (“medical patients”), including those suffering 
from cancer, who are immobilized in hospital due to 
an acute medical illness [15, 28, 254].
As mentioned before, there are still no studies on 
hospitalized cancer patients receiving conservative 
treatment in hospital. Although most of the hospitalized 
cancer patients, who do not receive surgical treatment 
require VTE prophylaxis due to concomitant risk fac-
tors, the decision regarding pharmacological prophy-
laxis administration in patients admitted to hospital and 
undergoing diagnostic procedures, as well as the ones 
receiving short-term chemotherapy infusions should be 
made individually. Each time it should be based on an 
individual assessment of risk of VTE as well as the risk of 
pharmacological prophylaxis [4, 9]. Similar controversies 
apply to patients with a central vein catheter — despite 
the fact that earlier reports suggest that it is reasonable to 
administer thromboprophylaxis in this group of patients 
with a central catheter, recent reports do not confirm 
that the routine use of pharmacological prophylaxis of 
VTE is justified in these individuals [15, 32, 33, 265].
In everyday practice low-molecular-weight hepa-
rin remains the most commonly administered drug in 
patients with potential indications for pharmacological 
thromboprophylaxis in hospital. The authors of these 
guidelines recommend to use low-molecular-weight 
heparins according to the manufacturer’s recommen-
dations. Thus far there are no reports confirming that 
it is possible to use these new anticoagulants (factor 
Xa inhibitors and factor II inhibitors) for thrombo-
prophylaxis in cancer patients receiving conservative 
treatment. Until there are trials correctly projected 
and performed, it is not recommended to use them for 
primary thromboprophylaxis in cancer patients. 
Guidelines
The prevention of venous 
thromboembolism in cancer  
patients receiving conservative 
treatment in hospital settings
Guideline 4.1
All cancer patients admitted to the hospital for dia-
gnostics and/or treatment should undergo individual 
risk assessment for VTE considering risk factors related 
to cancer and the therapy, as well as those related to 
the patient’s present condition and comorbidities [1A].
Guideline 4.2
It is recommended to use pharmacological throm-
boprophylaxis with low-molecular-weight heparin or 
low doses of unfractionated heparin in hospitalized 
cancer patients who are immobilized because of an 
acute medical ilness [1A].
Guideline 4.3
It is recommended to use thromboprophylaxis with 
low-molecular-weight heparin or low doses of unfractiona-
ted heparin in hospitalized cancer patients with limited 
mobility and/or the presence of other VTE risk factors, 
unless there are contraindications to pharmacological 
prophylaxis or high risk of bleeding [1B].
Guideline 4.4
It is suggested to consider the use of thrombo-
prophylaxis with low-molecular-weight heparin or low 
doses of unfractionated heparin in hospitalized patients 
with an active malignancy, unless there are contraindi-
cations to pharmacoprophylaxis or high risk of bleeding 
complications [2C].
Guideline 4.5
It is suggested to use mechanical methods of VTE 
prevention (most preferably intermittent pneumatic 
compression) in hospitalized patients with active cancer 
and indications for prevention of VTE, in the case of 
active bleeding or a high risk of bleeding complications, 
at least, until the bleeding risk decreases and admin-
istration of pharmacological prophylaxis becomes 
possible [2C].
Guideline 4.6
Routine pharmacological thromboprophylaxis is 
not recommended in patients with central venous 
catheters [1C].
Chapter 5. Post-discharge treatment  
of patients suffering from malignancy  
— thromboprophylaxis in patients with 
cancer treated in an outpatient settings
In the patients discharged after cancer surgery 
appropriate duration of thromboprophylaxis should be 
based on both: the type of performed surgery as well as 
on VTE risk factors presented in each case. Guidelines 
on postoperative prophylaxis were presented in the 
previous section concerning surgical patients (guidelines 
2.1–2.8). Aside surgery, risk factors for VTE including 
cancer treatment such as chemotherapy, hormone ther-
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apy, and combination therapy [32, 33, 38, 260, 270], type 
of the tumor and staging are also important [267, 268].
Chemotherapy used for cancer treatment may in-
crease VTE risk through many mechanisms, which lead, 
among others, to damaging or activation of endothelial 
cells, platelet activation, or reduction of the level of 
natural inhibitors of coagulation [269, 270]. Angiogen-
esis inhibitors, steroids and drugs affecting the patient’s 
endocrine system also have potential influence on he-
mostasis disorders and hypercoagulability [271–273].
Chemotherapy in hospitalized patients, immobility, 
and other potential risk factors for VTE justify the con-
sideration of thromboprophylaxis in most patients, who 
are admitted to hospital [9, 15, 254].
Despite the theoretical background as well as the 
fact that chemotherapy is believed to be a risk factor 
for VTE, thus far no prospective randomized trials were 
performed on efficacy of pharmacological prophylaxis in 
hospitalized patients, who receive chemotherapy. Due 
to the fact that populations of the patients receiving 
cancer treatment are inhomogeneous, both from the 
standpoint of the type, stage of the tumor and thera-
peutic methods used, it is difficult to estimate the value 
of predictive factors of VTE in patients treated with 
chemotherapy. At the same time, available studies refer 
to the fact that some patients receiving cancer treat-
ment are at higher risk of VTE [274, 275]. To evaluate 
this risk, the model of the VTE risk assessment based on 
the observation of patients undergoing chemotherapy 
in an outpatient setting was proposed by Khorana and 
co-workers (Table 3) [274].
It was suggested to support this model in subsequent 
studies with D-dimer test and soluble P-selectin assess-
ment. This increases sensitivity as well as the specificity 
of this scale [275].
While there is still no evidence to support the 
routine thromboprophylaxis in all patients receiving 
chemotherapy in outpatient setings, according to the 
performed studies there is evidence suggesting that 
pharmacological prophylaxis may be beneficial in at least 
some patients receiving this type of cancer treatment 
[276, 277]. This applies mostly to the patients with 
solid tumors, especially the ones with locally-advanced 
or metastatic pancreatic cancer as well as locally- 
-advanced lung cancer and metastatic lung cancer, 
where there are no contradictions and bleeding risk 
remains low [276]. 
The increased risk of thromboembolic complica-
tions in cancer patients may be related not only to 
the type and stage of cancer, but also to the systemic 
therapy that the patient received. The studies on ad-
ministration of thalidomide and lenalidomide in patients 
with multiple myeloma, which suggest that the rate of 
thromboembolic complication is high in combination 
therapy with any of these drugs along with steroids and/ 
/or chemotherapy serves as an example [278–281]. It 
is suggested that patients treated according to this plan 
should receive pharmacological VTE prophylaxis [9, 19, 
254]. Thromboprophylaxis may also be beneficial in pa-
tients receiving chemotherapy due to other indications, 
especially those, who have different risk factors such 
as chronic immobilization, history of venous thrombo-
embolism or other comorbidities or conditions that 
increase the risk of VTE (Chapter 4, Table 2).
Although in outpatients receiving chemotherapy, 
pharmacological prophylaxis is still not recommended 
Table 3. Risk assessment scale for venous thromboembolis in patients with cancer undergoing chemotherapy in out-patient set-
tings [according to 274]
Parameter of VTE Odds ratio (95% CI) Spot risk of VTE
Tumor location
• stomach, pancreas
• lung, lymphoma, gynecological, urinary bladder,  
   testicular
• breast, colon and rectum, head and neck
Platelet count before chemotherapy > 350 × 109/L
Hemoglobin level < 10 g/dL or administration of 
erythropoiesis stimulating agents
Leukocyte count before chemotherapy > 11 × 109/L
BMI ≥ 35 kg/m2
4.3 (1.2–15.6)
1.5 (0.9–2.7)
1.0 (baseline)
1.8 (1.1–3.2)
2.4 (1.3–4.2)
2.2 (1.2–4)
2.5 (1.3–4.7)
2
1
1
1
1
1
1
Number of points Risk category The risk of VTE
0 Low 0.8%
1.2 Intermediate 1.80%
≥ 3 High 7.1%
95% CI — 95% confidence interval; BMI — body mass index
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as a routine procedure, in this very group of pa-
tients many  prospective randomized clinical trials 
on pharmacological thromboprophylaxis in medical 
oncological patients were performed [277, 282–288]. 
The analysis of the results of these studies showed 
that the prevention of VTE with prophylactic doses 
of low-molecular-weight heparin was beneficial for at 
least some outpatients receiving chemotherapy, but 
at the same time indicates that there is a potential 
risk of bleeding complications in this patient group 
[278, 288, 289]. These findings as well as the still 
limited number of studies on this issue promotes an 
individual approach to the treatment and individual 
assessment of benefits, as well as the risks of throm-
boprophylaxis in these patients. Ben-Aharon et al. 
evaluated the results of 11 prospective clinical trials 
conducted on 6,942 patients receiving chemotherapy 
in outpatient settings, who received primary pharma-
cological thromboprophylaxis. This analysis proved 
a significant reduction in the incidence of VTE in 
the entire evaluated population (this was especially 
visible in patients suffering from lung cancer and 
pancreatic cancer), whereas there was no increase 
in incidence of major bleedings [17]. Meta-analysis 
performed by Che et al., brought similar conclusions 
in terms of efficacy of prophylaxis. The authors proved 
that pharmacological prophylaxis with low-molecu-
lar-heparin is beneficial, but at the same time increas-
es the risk of bleeding complications in outpatients 
undergoing chemotherapy [289]. At this point, it must 
be mentioned, that the results of each of the published 
studies significantly differ with respect to the type and 
the stage of tumors, cancer treatment as well as the 
obtained results, that is to say the reduction of throm-
boembolic complications and the incidence of bleeding 
complications. The example of that issue may be the 
effect of thromboprophylaxis on reduction of the inci-
dence of VTE in outpatients treated for lung cancer and 
pancreatic cancer, whereas the thromboprophylaxis has 
no influence on incidence of VTE in advanced breast 
cancer [283, 284, 286].
The analysis conducted by Cochrane on prospective 
clinical trials focusing on prophylaxis administration of 
oral anticoagulants in outpatients suffering from can-
cer proved the pharmacological thromboprophylaxis 
reduced the risk of VTE [290]. The authors, however, 
emphasize that the potential risk of bleeding complica-
tions should be taken into account, when the decision is 
made to administer such treatment. Similar conclusions 
were reached by Di Niso et al. based on randomized 
clinical trial on thromboprophylaxis in outpatients re-
ceiving chemotherapy [288].
Limited clinical data refers to prolonged thrombo-
prophylaxis in non-surgical patients (medical patients). 
In patients undergoing major surgery of the abdomen 
and pelvis, based on studies, it is justified to extend 
pharmacoprophylaxis up, whereas this was not con-
firmed in medical patients admitted to hospital on 
account of acute medical illness [291]. The EXCLAIM 
study aiming to assess the efficacy and safety of phar-
macological prophylaxis prolonged up to 4 weeks with 
low-molecular-weight heparin (in comparison to the 
standard prophylaxis duration) in medical patients, 
detected statistically significant reduction in VTE inci-
dence accompanied by statistically significantly higher 
risk of major bleedings [291]. It should be emphasized 
that cancer patients enrolled into the study constituted 
only a small group of analyzed patients, therefore thus 
far there are still no trials dedicated to the proper 
duration of thromboprophylaxis in cancer patients 
receiving conservative treatment. In this situation, as 
has been mentioned before, it is justified to assess the 
risk of VTE individually as well as benefits and risks of 
pharmacological prophylaxis in the patient group.
Guidelines
Post-discharge treatment of cancer 
patients — thromboprophylaxis in 
patients with cancer treated in  
an outpatient setting
Guideline 5.1
Each discharge patient should be assessed on the 
present VTE risk [1A].
Guideline 5.2
It is not recommended to use routine pharmaco-
logical thromboprophylaxis after discharge in all cancer 
patients receiving conservative treatment and receiving 
thromboprophylaxis during hospital stay. The decision 
to prolong prophylaxis in discharged patients should 
result from the individual risk assessment for VTE, as 
well as evaluation of the benefits and risks of pharma-
cological thromboprophylaxis [2B].
Guideline 5.3
Routine pharmacological thromboprophylaxis is 
not recommended in all patients receiving outpatient 
chemotherapy [1B]. In case of significant VTE risk, the 
indications for thromboprophylaxis in patients receiving 
chemotherapy in an outpatient setting should be deter-
mined individually based on evaluation of benefits and 
risks arising from prophylaxis [2B]. 
Guideline 5.4 
It is suggested to consider the use of pharmaco-
logical thromboprophylaxis in patients with locally 
advanced or metastatic pancreatic cancer [1B] or lung 
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cancer [2B] treated with chemotherapy when the risk 
of bleeding is low and there are no contraindications. 
Guideline 5.5
In patients with multiple myeloma receiving thalido-
mide or lenalidomide along with chemotherapy and/or 
dexamethasone it is suggested to implement pharma-
cological thromboprophylaxis with aspirin or LMWH in 
low-risk patients or LMWH in high-risk patients [2C].
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